<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Regeneron Pharmaceuticals Inc. REGN, +0.88% gained 2.1% in premarket trading on Wednesday, the day after the company said the U.S. government had purchased an additional 1.4 million doses of its monoclonal antibody treatment for COVID-19 for $2.9 billion. The treatment, which costs $2,100 per dose, is free to Americans at high risk of hospitalization and death who have tested positive or have been exposed to the virus.
...read full article on Market Watch
